<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

IDO to I DON’T – IDO1 Inhibitor Development News

As targeted immuno-oncology agents make impressive strides in cancer treatment, researchers are looking for agents that can augment response or overcome patient resistance. While small molecule IDO1 (indoleamine 2,3-dioxygenase-1) inhibitors were an early favorite among commercial drug discovery programs, disappointing Phase 3 clinical trials drove a rapid retreat of that investment – potentially stalling development of a powerful new immuno-oncology agent.

Early IDO1 Drug Development

IDO1’s role in immune suppression was first elucidated in studies of mouse pregnancy. Administering an IDO1 inhibitor to pregnant mice led to fetal rejection by maternal T cells. Therefore, inhibition of IDO1 (expressed by trophoblasts and macrophages) modulates the immune system and induces sufficient tolerance to prevent fetal rejection.

IDO1 functions in tryptophan catabolism, reducing the levels of extracellular tryptophan and increasing levels of the resultant product kynurenine. In the immune environment, tryptophan deprivation impairs antigen-dependent T cell activation, and requires both the restoration of tryptophan and an activation signal to restore T cell proliferation. Preclinically (and, researchers hoped, clinically), coadministration with checkpoint inhibitors could be one way to provide that activation signal.

IDO1 further modulates immune response through the increase in kynurenine. This acts as an immune suppressive agent by binding to the aryl hydrocarbon receptor (AhR), inducing dendritic cell and regulatory T-cells in turn.

It may also play a role in regulating the production and function of other suppressive cell types, such as myeloid derived suppressor cells (MDSCs).

IDO1 Overexpression on Tumors

Most human tumors constitutively express IDO1, and it may help induce immune tolerance of disease similar to its role in pregnancy. Overexpression of IDO1 by immunogenic mouse tumor cells prevents their rejection in preimmunized mice. In mice treated with an IDO1 inhibitor, T cell accumulation in tumor infiltrates is impaired, confirming the role of IDO1 in reducing tumor immune response.

Promising Early Clinical Data

Taken together, these intriguing preclinical data drove rapid clinical development of IDO1 inhibitors, producing tantalizing clinical efficacy data. Early data demonstrated antitumor activity in both melanoma and bladder cancer with multiple IDO1 small molecule inhibitors combined with anti-CTLA4, PD-1, or PD-L1 antibodies. Increases in tumor CD8+ T cells and inhibition of >90% of kynurenine production were also observed in treated patients.

Multiple companies rushed to invest in IDO inhibitors, either through internal programs (e.g. Incyte’s epacadostat) or via acquisitions and alliances, such as BMS’ $1.2 billion acquisition of Flexus, NewLink Genetics’ alliance with Genentech, and Pfizer’s partnership with iTeos.

However, as is common with early trials, the studies were either small, or lacked a control, comparator arm with patients treated with anti PD-1 only.

Disappointing Phase 3 Clinical Data

Earlier this year, data from larger Phase 3 studies of IDO1 inhibitors started to emerge.

The first study was the KEYNOTE-252/ECHO-301 trial of Incyte’s IDO1 inhibitor epacadostat. No benefit in progression free survival (PFS) or overall survival (OS) was observed with combined epacadostat + anti-PD-1 antibody treatment compared to anti-PD-1 monotherapy. This disappointing result led Incyte to shut down the trial in early April.

Incyte also cut back their other epacadostat clinical studies, from nine to essentially just two remaining trials of epacadostat in combination with anti-PD-1 in non-small cell lung cancer (NSCLC).

Incyte is not alone in purging IDO1 inhibitor clinical studies. Other programs which have been halted include:

Pharmacodynamic Insights and TDO Pathway Redundancy

Were there hints that could have predicted the lack of clinical response? Perhaps. Preclinically, IDO1 inhibition has only limited antitumor efficacy on its own. It requires combination with anti-PD-1 agents to achieve regression in animal models. IDO1 knockout mice also show no sign of overt autoimmune disease, unlike the PD-1 or CTLA-4 knockout mouse phenotypes.

Another hint may lie in the pharmacodynamics data reported by Incyte. The inhibitor resulted in >90% inhibition of kynurenine levels based on ex vivo stimulation of patient blood. However, overall reduction of kynurenine plasma levels maxed out at closer to 50% of pre-dose levels. It’s possible that this is insufficient for immune modulation.

The problem may also lie in pathway redundancy. In a healthy person, tryptophan 2,3-dioxygenase (TDO) also plays a major role in tryptophan catabolism. TDO actually controls >95% of tryptophan degradation but its expression is normally restricted to the liver.

However, TDO is also overexpressed in many tumors, including melanoma, and could be the reason why selective IDO inhibition is less effective than hoped. An alternative approach may be to identify an IDO/TDO dual inhibitor to better limit tryptophan catabolism. There are also potential downstream points of intervention, such as the AhR which uses kynurenine as a ligand.

The Future of IDO1 Inhibitors

There is a large body of preclinical data demonstrating the ability of IDO1 inhibitors to modulate the immune system. It may be a matter of finding the right molecule to effectively activate the immune system in combination with IDO inhibition.

Clinical Strategies

It’s known that a second signal is needed to activate IDO1 inhibited T cells – perhaps checkpoint inhibitors don’t actually fit the bill. All current clinical strategies, however, focused on combination with anti-PD-1, PD-L1, or anti-CTLA-4 agents.

Future clinical strategies may also focus on identifying potential biomarkers of response. Stratifying patients based on high IDO1 expression, low TDO expression, and presence of infiltrating lymphocytes might help maximize the ability of an IDO1 inhibitor to modulate antitumor immune response. This approach may be a testable clinical hypothesis to help identify responders. A close look at the IDO1 pathway and components may reveal other approaches.

There may also be potential for success in indications other than melanoma. The indication with the best response for patients treated with combination checkpoint inhibitor therapy (ipilumumab + nivolumab) is melanoma, a stunning 58% 3 year overall survival rate. Clearly melanoma is a disease where checkpoint inhibitors are highly active. However, most of the IDO1 data released to date is from melanoma. It’s possible that the IDO1 inhibitor efficacy is obscured by the effects of anti-PD-1. Other indications may be able to help discriminate an IDO1 inhibitor effect in combination.

Drug Development

Intriguing preclinical evidence and early clinical data caused an unusual amount of hype and excitement for this class of drugs, which in turn led to a frenzy of deals, acquisitions, clinical trials, and combinations. Now, with disappointing late stage clinical trial data, it appears there’s a similar rush to pass judgement on IDO1 inhibitors as a validation failure.

However, there may still be opportunity in pharmacological inhibitors of tryptophan catabolism, whether it be with novel clinical approaches with the current crop of IDO1 inhibitors or with a next wave of new molecules. A focus on a better understanding of the biology combined with a rational strategy may rescue these programs yet.

Related Posts